+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Age: 18Years +
All Genders
ID07890480

Evaluating Aztreonam-Avibactam for Resistant Bacterial Infections in Adults with Weakened Immune Systems An International Observational Study Comparing Treatment Outcomes

Led by Centro de Educación Medica e Investigaciones Clínicas Norberto Quirno · Updated on 2026-10-27

814

Participants Needed

1

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are studying the use of aztreonam-avibactam ATM-AVI, an antibiotic, in adults with weakened immune systems who have infections caused by highly resistant bacteria called metallo-b2-lactamase-producing Enterobacterales MBL-E. The study compares outcomes of patients treated with ATM-AVI to those previously treated with ceftazidime-avibactam plus aztreonam CZA-ATM. It aims to understand how well ATM-AVI works, how many patients recover or face complications, and what side effects occur during or after treatment. Participants receive antibiotic treatments chosen by their doctors as part of routine care without changes made by the study. Two groups are involved a prospective group receiving ATM-AVI and a retrospective group treated with CZA-ATM. The study collects detailed clinical and microbiological information, including treatment details and infection characteristics, following standardized methods. Participants in the prospective group are followed for up to 60 days after starting treatment to assess their recovery and any side effects. During the study, researchers review medical records and collect data on infections, treatments, and outcomes. They monitor clinical response, safety issues, mortality, and infection recurrence at specific times up to 60 days after treatment begins. Quality control ensures accurate and consistent data collection across centers. The main measure is all-cause mortality within 30 days of treatment start, along with other clinical and microbiological outcomes, including side effects related to blood, liver, kidney, allergic, gastrointestinal, neuropsychiatric symptoms, and infections such as Clostridioides difficile.

CONDITIONS

Brief Title

Aztreonam-Avibactam in Immunocompromised Hosts

Research Team

M

Maximiliano Gabriel Castro, MD

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here